Avadel End Period Cash Flow from 2010 to 2024

AVDL Stock  USD 10.44  0.17  1.60%   
Avadel Pharmaceuticals End Period Cash Flow yearly trend continues to be quite stable with very little volatility. The value of End Period Cash Flow is projected to decrease to about 28.3 M. From the period between 2010 and 2024, Avadel Pharmaceuticals, End Period Cash Flow regression line of its data series had standard deviation of  24,965,563 and standard deviation of  24,965,563. View All Fundamentals
 
End Period Cash Flow  
First Reported
1996-03-31
Previous Quarter
28.8 M
Current Value
28.6 M
Quarterly Volatility
28.5 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Avadel Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Avadel Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 10.4 M or Selling General Administrative of 159.3 M, as well as many indicators such as Price To Sales Ratio of 38.26, Dividend Yield of 0.0 or PTB Ratio of 13.55. Avadel financial statements analysis is a perfect complement when working with Avadel Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Avadel Pharmaceuticals Correlation against competitors.

Latest Avadel Pharmaceuticals' End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Avadel Pharmaceuticals PLC over the last few years. It is Avadel Pharmaceuticals' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Avadel Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
9.3M9.8M71.750.774.031.228.35%634%-29%46%-58%-9%100%
       Timeline  

Avadel End Period Cash Flow Regression Statistics

Arithmetic Mean30,924,448
Geometric Mean20,102,062
Coefficient Of Variation80.73
Mean Deviation20,686,116
Median28,252,715
Standard Deviation24,965,563
Sample Variance623.3T
Range71.2M
R-Value0.48
Mean Square Error519.4T
R-Squared0.23
Significance0.07
Slope2,655,121
Total Sum of Squares8725.9T

Avadel End Period Cash Flow History

202428.3 M
202331.2 M
202274 M
202150.7 M
202071.7 M
20199.8 M
20189.3 M

About Avadel Pharmaceuticals Financial Statements

Avadel Pharmaceuticals investors utilize fundamental indicators, such as End Period Cash Flow, to predict how Avadel Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
End Period Cash Flow31.2 M28.3 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Avadel Pharmaceuticals is a strong investment it is important to analyze Avadel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Avadel Pharmaceuticals' future performance. For an informed investment choice regarding Avadel Stock, refer to the following important reports:
Check out the analysis of Avadel Pharmaceuticals Correlation against competitors.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.09)
Revenue Per Share
1.036
Quarterly Revenue Growth
26.743
Return On Assets
(0.34)
Return On Equity
(1.00)
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
News Freq…Investor S…